In this study, pediatric devices were rare, emerged recently, and had longer review times and a higher proportion of registered clinical trials compared with nonpediatric devices, suggesting expectations for more pediatric-specific evidence despite unchanged statutory standards. To address gaps in pediatric device development, the FDA should standardize age labeling and validation requirements for AI-enabled technologies.
Zapotoczny et al. (2026) studied this question.